恒瑞医药：子公司收到SHR-1316(sc)注射液临床试验批准通知书

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of SHR-1316(sc) injection, a humanized anti-PD-L1 monoclonal antibody subcutaneous formulation intended for first-line treatment of extensive-stage small cell lung cancer [1] Company Summary - The drug SHR-1316(sc) is developed independently by the company and represents a significant advancement in its oncology portfolio [1] - The total research and development investment for the related project has reached approximately 815 million yuan [1]